Zevra Therapeutics Report issue

For profit Phase 2 Phase 3

Organization Overview

First Clinical Trial
2022
NCT05668754
First Marketed Drug
2018
acetaminophen (tylenol)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ZEVRA THERAP | Zevra Therapeutics

Active Ingredients

Marketed Drugs (2)

acetaminophen (tylenol) (2018)

benzhydrocodone (Apadaz) (2018)

Drugs in Phase 3 Trials (1)

Key: Zevra Therapeutics (0) Acquired (1)

celiprolol (1 trial)

Drugs in Phase 2 Trials (5)

Key: Zevra Therapeutics (1) Acquired (4)

imilecleucel-t (1 trial)

osanetant (1 trial)

serdexmethylphenidate (AZSTARYS) (1 trial)

sodium phenylbutyrate (buphenyl) (1 trial)

tovaxin (3 trials)

Indications

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 6